Company: STAA
Filing Date: 2025-10-06
Form Type: DFAN14A
Source: 0001213900-25-096599
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DFAN14A
Chunk 2
---
 at www.LetSTAARShine.com.

October 6, 2025

STAAR Surgical Company

25510 Commercentre
Dr.

Lake Forest, CA 92630

Dear Members of the Board:

You have decided it is time to sell
STAAR for per share. As you know, we strongly disagree with that decision.

One thing we can surely
agree on, however, is that this Board is, at best, one-for-two in making decisions about selling STAAR. With hundreds of millions of
dollars of shareholder money at stake, that is not good enough.

Sixteen months ago, you decided to
sell the Company to Alcon for per share in cash. You walked away from the table because of your belief in STAAR’s strong
business prospects. Yet now, with little change in the market, management’s financial forecasts, or STAAR’s opportunities,
you have decided to sell the Company for $28 per share.

“No” to $58.

“Yes”
to $28.

As your largest shareholder, we believe the Board got it
right the first time.

The Board wants
shareholders to believe that its decision to sell the Company now, at less than half the price, was based on a reassessment of the Company’s
business performance and outlook. But we cannot fathom how that could be.

The Company had a difficult
few quarters, to be sure, as demand in China slowed temporarily and excess inventory was worked off. But now, STAAR’s prospects
are sound, with sufficient cash, strong demand, new products ready to be launched, and cost savings opportunities to drive future profitability.
In fact, if management’s own projections are achieved, the company will experience double-digit revenue growth and profit margins
that are among the highest of any midsized medical technology company in the world. And those projections are consistent with the company’s
prospects at the time you rejected $58 per share.

We can only assume that the Board does not believe
in this management’s latest forecast. But shareholders have no reason to trust your assessment of the future. When you decided
not to sell for $58 per share, for example, you evidently did not foresee the transitory troubles in China that would occur six months
later. If you could not foresee a problem that was mere months away - and one that you now claim caused a collapse of enterprise value
by more than 50% - why should any investor rely on your judgment or foresight today?

We continue